Want to see NRSN full AI Analyst Report?
NRSN Stock Chart & Stats
$0.41
-$0.02(-2.51%)
At close: 4:00 PM EDT
$0.41
-$0.02(-2.51%)
Day’s Range― - ―
52-Week Range$5.00 - $26.62
Previous Close$0.58
Volume86.30K
Average Volume (3M)21.31K
Market Cap
$13.34M
Enterprise Value$24.53
Total Cash (Recent Filing)$166.00K
Total Debt (Recent Filing)$170.00K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.91
Shares Outstanding1,896,902
10 Day Avg. Volume37,574
30 Day Avg. Volume21,312
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.63
Price to Sales (P/S)0.00
P/FCF Ratio-0.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.50Price Target Upside1973.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ManufacturingNRSN has completed the scale-up of its manufacturing process of PrimeC to commercial scale.
Product DevelopmentNeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS), and previously received feedback from the FDA regarding the Phase trial 3 design for PrimeC.
Bears Say
Financial ConstraintsWhile the data previously generated for PrimeC has been promising, the company still has capital constraints, including its 'baby shelf' limitations, which will make it difficult to raise sufficient capital to fully finance the Phase 3 trial.
Funding UncertaintyNeuroSense still has not signed a definitive agreement with the previously-undisclosed partner to fund PrimeC’s Phase 3 program and commercialization.
Regulatory ChallengesThe company received negative feedback from Health Canada regarding an accelerated approval pathway for PrimeC for treating ALS.
Neurosense Therapeutics Ltd. News
NRSN FAQ
What was Neurosense Therapeutics Ltd.’s price range in the past 12 months?
Neurosense Therapeutics Ltd. lowest stock price was $5.00 and its highest was $26.62 in the past 12 months.
What is Neurosense Therapeutics Ltd.’s market cap?
Neurosense Therapeutics Ltd.’s market cap is $13.34M.
When is Neurosense Therapeutics Ltd.’s upcoming earnings report date?
Neurosense Therapeutics Ltd.’s upcoming earnings report date is Dec 02, 2026 which is in 76 days.
How were Neurosense Therapeutics Ltd.’s earnings last quarter?
Neurosense Therapeutics Ltd. released its earnings results on Sep 02, 2026. The company reported -$3.9 earnings per share for the quarter.
Is Neurosense Therapeutics Ltd. overvalued?
According to Wall Street analysts Neurosense Therapeutics Ltd.’s price is currently Undervalued.
Does Neurosense Therapeutics Ltd. pay dividends?
Neurosense Therapeutics Ltd. does not currently pay dividends.
What is Neurosense Therapeutics Ltd.’s EPS estimate?
Neurosense Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neurosense Therapeutics Ltd. have?
Neurosense Therapeutics Ltd. has 1,896,902 shares outstanding.
What happened to Neurosense Therapeutics Ltd.’s price movement after its last earnings report?
Neurosense Therapeutics Ltd. reported an EPS of -$3.9 in its last earnings report. Following the earnings report the stock price went down -2.214%.
Which hedge fund is a major shareholder of Neurosense Therapeutics Ltd.?
Currently, no hedge funds are holding shares in NRSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
NRSN Stock 12 Month Forecast
Average Price Target
$8.50
▲(1973.17% Upside)
Technical Analysis
Ownership Overview
18.61% Insiders
0.04% Mutual Funds
0.21% Other Institutional Investors
81.14% Public Companies and
Individual Investors